When is the next results date for Concord Biotech?

No Upcoming Board Meetings

Has Concord Biotech declared dividend?

Yes, Concord Biotech Ltd has declared an 875% dividend, amounting to ₹8.75 per share, with an ex-date of June 21, 2024. While the 1-year total return is 33.35%, the recent 6-month return is -10.59%.

Yes, Concord Biotech Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 875%<BR>- Amount per share: 8.75<BR>- Ex-date: Jun-21-2024<BR><BR>Dividend Yield: 0.47%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -10.59%, the dividend return was 0%, resulting in a total return of -10.59%.<BR><BR>For the 1-year period, the price return was 32.75%, the dividend return was 0.60%, leading to a total return of 33.35%.<BR><BR>Over the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0% and the dividend return was also 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Concord Biotech has declared a significant dividend, the total returns over various periods show mixed performance, with a notable positive return in the 1-year period but negative returns in the recent 6-month period.

Is Concord Biotech overvalued or undervalued?

As of August 21, 2023, Concord Biotech is considered very expensive and overvalued, with high valuation ratios significantly exceeding its peers, despite a strong 38.84% return over the past year.

As of 21 August 2023, Concord Biotech's valuation grade has moved from does not qualify to very expensive. The company is currently overvalued based on its high valuation ratios, including a PE ratio of 54.06, an EV to EBITDA of 39.12, and a PEG ratio of 2.41. These figures significantly exceed those of its peers, such as Sun Pharmaceutical Industries Ltd. with a PE of 35.25 and Divi's Laboratories Ltd. with an EV to EBITDA of 57.35.<BR><BR>In comparison to its peers, Concord Biotech's financial metrics suggest it is trading at a premium, indicating a lack of justification for its current price. While the company has shown strong returns over the past year, outperforming the Sensex with a 38.84% return compared to the Sensex's 7.53%, the overall valuation still reflects an overvalued status in the current market landscape.

Who are the peers of the Concord Biotech?

Concord Biotech's peers include Pfizer, ERIS Lifescience, Astrazeneca, OneSource Specialty, Alembic Pharma, Neuland Labs, Jubilant Pharma, Natco Pharma, and Sai Life. ERIS Lifescience has the highest 1-year return at 74.62%, while Concord Biotech's return is 7.74%, higher than Natco Pharma's -20.35%.

Peers: The peers of Concord Biotech are Pfizer, ERIS Lifescience, Astrazeneca Phar, OneSource Speci., Alembic Pharma, Neuland Labs., Jubilant Pharmo, Natco Pharma, and Sai Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Pfizer, ERIS Lifescience, Astrazeneca Phar, Alembic Pharma, Neuland Labs., and Natco Pharma, and the rest. Below Average management risk is noted for Jubilant Pharmo, while Average management risk is seen at Sai Life. Growth is rated as Excellent for OneSource Speci., Good for Concord Biotech and Natco Pharma, Average for Neuland Labs., and Below Average for Pfizer, ERIS Lifescience, Astrazeneca Phar, Alembic Pharma, and the rest. Capital Structure is Excellent for Pfizer, ERIS Lifescience, Astrazeneca Phar, Alembic Pharma, Neuland Labs., and Natco Pharma, while Below Average is noted for OneSource Speci., and Average for Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is ERIS Lifescience at 74.62%, while the lowest is Natco Pharma at -20.35%. Concord Biotech's 1-year return of 7.74% is higher than Natco Pharma's but lower than ERIS Lifescience's. Additionally, Natco Pharma and Concord Biotech have negative six-month returns.

Who are in the management team of Concord Biotech?

As of March 2023, the management team of Concord Biotech includes Sudhir Jairam Vaid (Chairman & Managing Director), Ankur Vaid (Joint Managing Director & CEO), and several independent and non-executive directors, totaling 13 key members who guide the company's governance and strategy.

As of March 2023, the management team of Concord Biotech includes the following individuals:<BR><BR>1. Sudhir Jairam Vaid - Chairman & Managing Director<BR>2. Ankur Vaid - Joint Managing Director & CEO<BR>3. Ravi Kapoor - Non Executive Director<BR>4. Rajiv Agarwal - Nominee<BR>5. Utpal Sheth - Nominee<BR>6. Amit Varma - Nominee<BR>7. Bharti Khanna - Independent Director<BR>8. Anil Katyal - Independent Director<BR>9. Amitabh Thakore - Independent Director<BR>10. Arvind Agarwal - Independent Director<BR>11. Jayaram Easwaran - Independent Director<BR>12. Mandayam Chakravarthy Sriraman - Independent Director<BR>13. S Prakash - Vice President & Company Secretary<BR><BR>This team plays a crucial role in the governance and strategic direction of the company.

What does Concord Biotech do?

Concord Biotech Ltd is a mid-cap pharmaceutical and biotechnology company, originally founded in 1984, with net sales of ₹4,299 Cr and a net profit of ₹1,404 Cr as of March 2025. The company has a market cap of ₹19,274 Cr and key metrics include a P/E ratio of 52.00 and a return on equity of 20.62%.

Overview: <BR>Concord Biotech Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History: <BR>Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited in 1984. The company changed its name to Concord Biotech Limited in 2001, transitioning to a Public Company. The latest quarterly results reported are for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 4,299 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1,404 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 19,274 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 52.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.18 <BR>Return on Equity: 20.62% <BR>Price to Book: 12.14 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Concord Biotech?

The top shareholders of Concord Biotech include Sudhir Vaid, who holds 28.84%, followed by 22 mutual funds with 5.16%, 92 foreign institutional investors with 9.35%, and the Aryaman Jhunjhunwala discretionary trust at 8.03%. Individual investors own a total of 6.94% of the company.

The top shareholders of Concord Biotech include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sudhir Vaid, owning 28.84% of the company. Additionally, there are 22 mutual funds that collectively hold 5.16% of the shares, while 92 foreign institutional investors (FIIs) hold 9.35%. The highest public shareholder is the Aryaman Jhunjhunwala discretionary trust, which holds 8.03%. Individual investors collectively own 6.94% of the company.

How big is Concord Biotech?

As of 24th July, Concord Biotech Ltd has a market capitalization of 20,411.00 Cr, with recent net sales of 1,200.08 Cr and net profit of 371.64 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Concord Biotech Ltd has a market capitalization of 20,411.00 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,200.08 Cr, while the sum of Net Profit for the same period is 371.64 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 1,526.65 Cr and Total Assets valued at 1,700.71 Cr.

Are Concord Biotech latest results good or bad?

Concord Biotech's latest results are disappointing, with net sales declining 32% to Rs 203.99 crore and Profit Before Tax falling 60% to Rs 45.05 crore, marking the lowest performance in recent quarters across key financial metrics.

Concord Biotech's latest financial results for the quarter ending June 2025 are disappointing. The company reported net sales of Rs 203.99 crore, which is a significant decline of 32% compared to the average net sales of Rs 300.02 crore over the previous four quarters. This marks the lowest sales figure recorded in the last five quarters, indicating a troubling trend.<BR><BR>Profit Before Tax (PBT) also fell sharply to Rs 45.05 crore, down 60% from the average PBT of Rs 112.53 crore in the prior four quarters. Profit After Tax (PAT) decreased by 52.6%, reaching Rs 44.06 crore, again the lowest in recent history.<BR><BR>Additionally, operating profit and operating profit margin have declined, with operating profit at Rs 61.40 crore and a margin of 30.10%, both reflecting the lowest performance in recent quarters. Earnings per share (EPS) dropped to Rs 4.21, signaling reduced profitability for shareholders.<BR><BR>Overall, the financial performance indicates a challenging period for Concord Biotech, with significant declines across key metrics.

Is Concord Biotech technically bullish or bearish?

As of October 7, 2025, Concord Biotech's trend is mildly bearish due to bearish signals from the MACD and Bollinger Bands, despite some underlying buying pressure indicated by the On-Balance Volume.

As of 7 October 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and Bollinger Bands indicating bearish signals. The daily moving averages also reflect a bearish outlook. However, the On-Balance Volume (OBV) shows bullish strength on both weekly and monthly time frames, suggesting some underlying buying pressure. Overall, the lack of strong bullish indicators and the presence of bearish signals in multiple areas indicate a cautious stance on Concord Biotech.

How has been the historical performance of Concord Biotech?

Concord Biotech has shown consistent growth over the past four years, with net sales increasing from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, and profit after tax rising from 178.57 Cr to 372.96 Cr. However, cash flow management faced challenges, with a decline in operating cash flow and a net cash outflow in the latest fiscal year.

Answer:<BR>The historical performance of Concord Biotech shows a consistent growth trajectory in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Concord Biotech's net sales have increased from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed a similar pattern, rising from 712.93 Cr to 1,200.09 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 439.66 Cr in Mar'22 to 693.76 Cr in Mar'25, indicating increased operational costs. Operating profit (PBDIT) saw a significant rise from 296.69 Cr in Mar'22 to 550.78 Cr in Mar'25, showcasing improved profitability. Profit before tax increased from 241.16 Cr to 495.87 Cr, while profit after tax rose from 178.57 Cr to 372.96 Cr, demonstrating effective cost management and revenue generation. The earnings per share (EPS) improved from 16.72 in Mar'22 to 35.53 in Mar'25, reflecting enhanced shareholder value. On the balance sheet, total assets grew from 1,312.79 Cr to 2,034.25 Cr, and total liabilities increased from 1,312.79 Cr to 2,034.25 Cr, indicating a robust growth in the company's financial position. Cash flow from operating activities showed a slight decline from 265.00 Cr in Mar'24 to 244.00 Cr in Mar'25, while net cash outflow was recorded at -14.00 Cr in Mar'25, down from a positive inflow of 11.00 Cr in Mar'24. Overall, Concord Biotech has demonstrated strong growth in sales, profits, and asset base, although cash flow management appears to have faced some challenges in the latest fiscal year.

Should I buy, sell or hold Concord Biotech?

Which are the latest news on Concord Biotech?

Why is Concord Biotech falling/rising?

As of 16-Dec, Concord Biotech Ltd's stock price is slightly rising at 1,370.10, but it has experienced significant declines over the year, with a year-to-date drop of 38.00%. Despite increased investor interest, the overall outlook remains negative due to poor long-term growth and high valuation metrics.

As of 16-Dec, Concord Biotech Ltd's stock price is rising slightly, currently at 1,370.10, with a change of 7.45 (0.55%) upwards. Despite this minor increase, the stock has shown a significant decline over longer periods, with a year-to-date drop of 38.00% and a one-year return of -34.43%. This indicates a poor performance relative to the broader market, as the Sensex has increased by 8.37% year-to-date.<BR><BR>The stock is currently trading 2.6% above its 52-week low, suggesting it is close to a critical support level. However, it is also trading below its moving averages across various time frames, which typically signals a bearish trend. On a positive note, there has been a notable increase in investor participation, with delivery volume rising by 353.43% compared to the five-day average, indicating some renewed interest in the stock.<BR><BR>Despite the slight rise today, the overall outlook remains concerning due to poor long-term growth, as evidenced by a -0.48% annual growth rate in operating profit over the last five years and a significant drop in profits in recent quarters. The company's return on equity (ROE) is relatively high at 19.17%, but the stock is considered expensive with a price-to-book value of 7.8, which may deter potential investors. Overall, while there is a minor uptick in price, the underlying fundamentals suggest a challenging environment for Concord Biotech Ltd.